Regulatory requirements in the pharmaceutical and healthcare sectors are essential for safeguarding public health, ensuring product quality, and fostering innovation. These regulations, shaped by historical events affecting patient safety, encompass guidelines from various government agencies and international organizations. The International Council for Harmonisation (ICH) plays a pivotal role in promoting global regulatory harmonization, addressing the complexities arising from divergent national standards. Agencies such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) enforce stringent safety and efficacy standards for drug approvals, while the World Health Organization (WHO) coordinates global health initiatives and establishes essential medicine lists. The development of praziquantel (PZQ) exemplifies the regulatory process, showcasing the challenges and successes in bringing effective treatments to market. The recent positive scientific opinion of (R)-PZQ from the Committee for Medicinal Products for Human Use (CHMP) illustrates the importance of robust regulatory strategies and collaboration among stakeholders to enhance access to essential medicines, particularly in low- and middle-income countries.